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Abstract
Background: The One Health approach is emerging in response to the development of bacterial resistance. To the
best of our knowledge, the possibility to use this approach in a clinical context has not yet been explored. Thus, in
this paper, we report the procedures to implement a prospective observational study of diagnostic pathways in human
and canine patients with suspected urinary tract infection as a means to assess the feasibility and synergistic value of
setting up One Health clinical research projects and interventions.
Methods/design: A prospective observational study will compare different diagnostic pathways (i.e., 16 possible
combinations of diagnostic tools) to gold standard in human and veterinary primary care practice in Denmark.
Fifty primary care practices and 100 veterinary clinics will each consecutively include 20 human patients or 8–10
dogs, respectively. Data will be collected at practice and patient level comprising (a) information about the organization
of the practice and access to different diagnostic tools, (b) information about clinical history, diagnostic path and
treatment during the index consultation, (c) information about severity of symptoms during the 7–10 days following
inclusion, and (d) urine culture (type of microorganism and susceptibility test). The feasibility and synergistic value of
conducting future research, and/or designing common interventions, will be assessed by evaluating the comparability
of human primary care and veterinary primary care with respect to study implementation and study results.
Discussion: Results from this study will give an insight into the feasibility and synergistic value of setting-up One Health
research projects in a clinical context. This is crucial if we are to embrace the One Health approach, as a legitimate
strategy to implement common interventions aimed at influencing the diagnostic process in human and canine
patients in order to decrease inappropriate use of antibiotics.
Trial registration: The study in humans has been registered in ClinicalTrials.gov NCT02249273.
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Background
Animals and humans share a common environment and
may thereby impact each other’s health. One Health is
defined as the collaborative effort of multiple disciplines
to attain optimal health for people, animals, and the en-
vironment [1] by studying and controlling the risks fac-
tors that can originate diseases at the confluence of
humans, animals, and their interacting environment.
For many years, this approach was only used in the
area of Translational Science [2] (i.e., animal models for
testing new medicaments). Nonetheless during the last
15 years, the One Health approach has gained recogni-
tion about its effectiveness for mitigating and increasing
the understanding of the mechanisms involved in the
spread of infectious diseases [3, 4]. Consequently, this
approach has been mostly developed in the public health
area regarding management of zoonotic diseases [5] and
surveillance of emerging diseases [6].
Now, new routes have started to be explored as a means
to take not only advantage of the potential synergism of
the similarities between species but also advantage of the
similarities regarding the required skills needed by medical
doctors, veterinarians, and Public Health professionals,
when dealing with infectious diseases [7].
In that sense, the uncontainable development of anti-
biotic resistance in humans and animals [8, 9] has exposed
the fragility of the species barrier [10], revealing the need
to promote a cross-sectorial collaboration that follows a
One Health strategy, not only at a public health level but
also in a clinical context.
Inappropriate use of antibiotics is one of the most im-
portant determinants for the development of antibiotic-
resistant bacterial strains [11]. Consequently, during the
past two decades, several studies have tried to identify
the determinants of antibiotic prescription in humans
and animals [12–14]. The overall conclusion is that a
variety of factors influence the final decision to prescribe
antibiotics, including characteristics of the patient, the
prescriber, the health system, and the society.
Previous studies have shown that uncertainty about the
bacterial or viral origin of the symptoms [15] and risk-
avoidance attitudes [16] are associated with inappropriate
prescribing of antibiotics, implying that use of accurate
diagnostic tools is crucial during the decision-making
process of antibiotic prescription.
Urinary tract infection (UTI) is a frequent reason to
prescribe antibiotics, both in humans at primary care
level [17] and in companion animals [18], fuelling the
development of antibiotic-resistant strains, specifically in
gram-negative rods such as extended spectrum beta-
lactamase (ESBL)-producing Escherichia coli [19].
General practitioners (GPs) and companion animal
veterinarians (CAVs) face two common challenges: (a) lack
of consensus regarding the validity of different diagnostic
approaches in human and canine patients with suspected
UTI and, (b) lack of evidence regarding the impact of the
use of these diagnostic approaches on the clinical and
microbiological recovery.
The lack of consensus and evidence is highlighted in the
current international recommendations regarding treat-
ment of UTI in humans and companion animals, which
tend to focus on issues of antibiotic treatment (drug selec-
tion, dose, duration, and route of administration) with less
emphasis on the diagnostic process [18, 20].
Several diagnostic tools are available in human and veter-
inary practice to identify patients with UTI, but there is no
consensus about the added value of using different diag-
nostic pathways. For example, some studies of human pa-
tients with uncomplicated UTI have demonstrated that
symptoms alone lead to overuse of antibiotics [21–23],
while other studies have concluded that the combination
of specific symptoms may justify the empirical prescription
of antibiotics without a need for further testing [24, 25].
Furthermore, studies assessing the validity of micros-
copy show wide variation in sensitivity (60–100 %) and
specificity (49–100 %) to predict significant bacteriuria
in humans [26, 27] and in companion animals [28–29].
There are no studies comparing microscopy with more
recent diagnostic tools such as point-of-care culture and
susceptibility testing in human and veterinary primary
care practice.
In this paper, we describe the procedures for conducting
a prospective observational diagnostic study in human
and canine patients with suspected UTI. The aims of the
study are (i) to assess the impact of the diagnostic process
on proper use of antibiotics in human and canine patients
with suspected UTI, (ii) to assess the feasibility (i.e., degree
of comparability of the implementation phase), and (iii)
the synergistic value (i.e., degree of comparability of the
results) of the One Health approach in order to design
common future interventions and research.
Methods/design
Design and setting
The study is designed as a prospective observational
study comparing different diagnostic strategies with gold
standard (culture and susceptibility testing at a reference
microbiological laboratory) in human and veterinary pri-
mary care practice in Denmark.
There are five common diagnostic tests, which can
be used in humans and animals with suspected UTI
(Additional file 1). The interpretation of these tests
can vary due to differences in the prevalence of some
microorganisms, the urine collection technique, and
cut-off point for significant bacteriuria on positive
cultures (Additional file 2).
The clinical use of these diagnostic tools corresponds
to 16 potential diagnostic pathways that are summarized
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in Fig. 1 and are mainly divided into those pathways in
which the result is available during the consultation
(signs and symptoms, dipsticks, microscopy) or those in
which the result is available 1–3 days after the consult-
ation (culture and susceptibility test in practice, culture
and susceptibility test at a reference microbiology
laboratory).
Population
Fifty practices in the capital region and 100 veterinary
clinics in Denmark will consecutively include minimum
20 human patients or 8–10 dogs, respectively. The inclu-
sion criteria are summarized in Table 1.
The study is planned to last 2 years. Every 6 months,
general practitioners from the capital region and veteri-
narians from the whole country will receive a personal
invitation letter to participate until we get the expected
number of professionals.
Data collection
Figure 2 summarizes the data collection process.
Before enrollment of patients, the contact person at each
practice/veterinary clinic (i.e., general practitioner, nurse,
and veterinarian) will complete a background question-
naire about the organization of the practice/clinic and the
access to different diagnostic tools.
On the day of the index consultation, the clinical history,
diagnostic path, treatment, and other relevant decisions
made during the consultation will be registered. Health
care providers will consecutively include patients that fulfill
inclusion criteria. Age and gender of human patients that
fulfill the inclusion criteria but refuse to participate in the
study will be registered.
The patient or the dog owner will keep a diary during the
7–10 days following inclusion. Human patients will be
asked about potential risk factors for harboring resistant
bacteria, specifically ESBL-resistant E. coli [30]. Both
human patients and dog owners will register severity of
clinical symptoms daily during 7–10 days. The validation of
the severity score in humans will be published elsewhere.
Automatic text message reminders will be sent to the
patient or dog owner to remind them to fill out and return
the diary and to remember to send in a second urine sam-
ple for culture 2 weeks after the index consultation.
For those patients attending general practice, further in-
formation about co-morbidities, hospitalizations, and use
of antibiotics will be collected from The Danish National
Patient Register and The Danish National Prescription
Register.
Urine samples
A urine sample will be collected from each patient and
dog and used for two purposes: (a) gold standard culture
and susceptibility testing at a reference laboratory and
(b) on-site diagnostic procedures (i.e., sign and symp-
toms, sticks, microscopy, culture and susceptibility test
Fig. 1 Diagnostic path in patients with suspected UTI in human and veterinary primary care practices in Denmark. The decision tree illustrates the
different diagnostic pathways that can be taken during the diagnostic process of a patient with a suspected UTI. The diagnostic pathways are divided
into those pathways in which the result is available during the consultation (signs and symptoms, dipsticks, microscopy) and those in which the result is
available 1–3 days after the consultation (culture and susceptibility test in practice, culture and susceptibility test at a reference microbiology laboratory)
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Table 1 Summary of the inclusion and exclusion criteria for patients presenting with signs of urinary tract infection
General practice Veterinary practice
Inclusion criteria ≥18 years of age Dogs of all ages
Acute dysuria and/or frequency Acute dysuria, frequency, hematuria,
strangury, and/or malodorous urine
Patient consulting during office hours
A suspected UTI A suspected UTI
Patient signs written informed consent Owner signs written informed consent
Exclusion criteria Currently taking antibiotics Antibiotic treatment in the last 3 weeks
Inability to fill in the symptom diary Systemic illness
Inability to provide a urine sample Known chronic disease(s)
Inability to sign an inform consent Chronic, recurrent or relapsing UTI
(three times or more in a year)
Previous participation in this study Inability to collect a urine sample
Previous participation in this study
UTI urinary tract infection
Fig. 2 Data collection flow chart. The diagram shows the phases and milestones of data collection before, during, and after the index consultation in
human and veterinary primary care practices
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in the practice/clinic). Human patients will deliver a
second urine sample for culture 14 days after the index
consultation in order to evaluate the microbiological
effect of the treatment.
Gold standard
Urine samples will be sent by certified mail to the refer-
ence laboratories. For general practice, urine samples
will be analyzed at the National Center for Surveillance,
Prevention and Control of Infectious Diseases—Statens
Serum Institute (SSI)—and urine samples from veterin-
ary practices will be analyzed at the Department of Vet-
erinary Disease Biology, University of Copenhagen
(SUND VET DIAGNOSTIK (SVD)). Mid-stream urine
and catheter-collected urine samples will be sent in boric
acid preservation tubes (10 mL Sarstedt monovette and
BD Vacutainer C&S Boric Acid Kit), and urine sampled
by cystocentesis will be sent in plain sterile vacutainer
tubes. Laboratory staff members processing and analyz-
ing the cultures will not have access to any clinical
information.
At SSI, aerobic urine culture will be performed with 1 μL
on blood agar plate and “blue” agar plate (SSI Diagnostics,
Denmark) and 100 μL on ESBL chromogenic culture
media (Brilliance ESBL AGAR; Oxoid, UK).
ESBL plates will be examined after 1 day of incubation
and read according to the color chart provided by the
manufacturer. Phenotypic confirmation of ESBL produc-
tion is performed by the Total ESBL Confirm Kit 98014
(Rosco Diagnostics).
Susceptibility testing will be performed and interpreted
according to EUCAST standards [31] on Mueller-Hinton
agar plates using Neo-Sensitabs (Sulfamethoxazole,
trimethoprim, ampicillin, amoxicillin-clavulanic acid,
cefpodoxime, ciprofloxacin, and nitrofurantoin, Rosco
Diagnostics).
At SVD, samples will be cultured on bovine blood agar
plates as well as MacConkey agar plates. Each half of the
bovine blood agar plates will be prepared with sterile
loops containing 1 μL and 10 μL urine, respectively. The
MacConkey agar plates will be prepared with sterile
loops containing 1 μL of each urine sample. All plates
will be incubated aerobically overnight at 37 °C.
When reading the plates, any growth on the MacCon-
key plate will be noted. If growth is observed on the bo-
vine blood agar plates, the colonies will be inspected and
the number of colony-forming units (CFU) per milliliter
of urine will be counted and noted. If more than one
type of colony is present, each type will be subcultured
on a separate bovine blood agar plate and incubated
overnight at 37 °C before reading the next morning.
Each type of colony will be identified to species level by
matrix-assisted laser desorption/ionization time of flight
(MALDI-TOF) mass spectrometry (Vitek MS RUO,
France). Antimicrobial susceptibility will be tested by
broth microdilution (Sensititre® COMPAN1F; TREK
Diagnostic System Ltd., West Sussex, UK) according
to the Clinical and Laboratory Standards Institute
(CLSI) [32].
While the study is ongoing, GPs and veterinarians will
not receive the results from the reference laboratories in
order to avoid impacting the diagnostic procedures and
case management (review bias).
Outcomes
The outcomes and source of data related to the diagnos-
tic pathways are presented in Table 2.
The feasibility and synergistic value of conducting future
research, and/or designing common interventions, will be
assessed by evaluating the comparability of human pri-
mary care and veterinary primary care with respect to (i)
the study implementation and (ii) the study results. Feasi-
bility and synergistic value outcomes are summarized in
Table 3.
Sample size calculation
Due to the observational design of the study, the distri-
bution of the diagnostic pathways is currently unknown.
Nonetheless, the calculated sample sizes are based on
the following assumptions: (a) the four diagnostic path-
ways that influence the decision during the consultation
(i.e., sign and symptoms, sticks, microscopy—Fig. 1) are
used in 60 % of the human patients and 80 % of the
dogs, (b) a correct decision (i.e., appropriate use of anti-
biotics—Fig. 3) is made for 60 % of the human patients
and 55 % of the dogs, while (c) an incorrect decision
during the consultation is made for 40 % of the human
patients and 45 % of the dogs in which any of the
remaining 12 diagnostic pathways (involving culture
and/or susceptibility testing) are performed. Intra-class
correlation = 0.2, α = 0.05 and β = 0.2. Based on these as-
sumptions, 900 patients from 50 practices and 800 dogs
from 100 veterinary clinics are required.
Data management
Two different databases will be created to store data
from general practice and data from veterinary clinics,
respectively. The data from general practice will be
stored in an encrypted drive as it contains the personal
identification number from each patient (CPR number)
and the national identification number at practice level
(ydernummer). All data will be typed twice and will be
screened for data entry errors and extreme values using
tables, plots, and specific commands using SAS software,
Version 9.3 of the SAS System for Windows 7; copyright
(c) 2002–2010 by SAS Institute Inc., Cary, NC, USA.
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Statistical analysis
The result from the “gold standard” will provide infor-
mation to assess proper use of antibiotics as described in
Fig. 3. First- and second-line antibiotics for the treat-
ment of UTI in humans and dogs are presented in
Table 4.
Sensitivity, specificity, likelihood ratios, and receiver-
operating characteristic (ROC) curves will be used to as-
sess the accuracy of the diagnostic pathways.
A hierarchical logistic regression model will be con-
structed to assess the association between the use of dif-
ferent diagnostic pathways and proper use of antibiotics,
while taking into consideration characteristics at patient
and clinic level. The propensity score matching tech-
nique will be employed to adjust for pre-test imbalances
in the different groups of diagnostic approaches.
Descriptive statistics looking at differences in feasibil-
ity and synergistic value outcomes between the medical
and veterinary study groups will be presented. A qualita-
tive assessment of the extent of comparability between
the veterinary and medical disciplines will be deduced,
and based on this, areas for meaningful future collabor-
ation (i.e., common educational interventions/research)
will be identified.
Ethics and dissemination
The study does not represent any risk for the patients
due to the observational design. The diagnostic process
and the treatment will be registered as it is currently
done in everyday practice. Consequently, the course of
disease and the treatment strategies are not affected by
participation or not in the study.
The Regional Ethical Committee has approved devel-
opment of the biobank, and informed written consents
Table 2 Primary and secondary outcomes with data sources to investigate the impact of diagnostic and treatment procedures in
patients with suspected UTI in human and veterinary primary care practices in Denmark
General practice Veterinary practice
Primary outcome Source of data Primary outcome Source of data
Proportion of (i) appropriate decisions to treat
with antibiotics and (ii) appropriate choices of
antibiotic for each diagnostic path
Case report form Proportion of (i) appropriate decisions to treat
with antibiotics and (ii) appropriate choices of
antibiotic for each diagnostic path
Case report form
Difference in the percentage of patients with
appropriate antibiotic treatment when comparing
diagnostic pathways during the consultation and
diagnostic pathways after the consultation
Culture report
from SSIa
Difference in the percentage of patients with
appropriate antibiotic treatment when comparing
diagnostic pathways during the consultation and
diagnostic pathways after the consultation
Culture report
from SVDa
Secondary outcomes Secondary outcomes
Validity of each diagnostic path Case report form Validity of each diagnostic path Case report form
Culture report
from SSI
Culture report
from SVD
Number of days until clinical cure (i.e., first
day without symptoms from the urinary tract)
Symptom diary Number of days until clinical cure (i.e., first day
without clinical signs from the urinary tract
Symptom diary
Prevalence of uro-pathogens Culture report
from SSI
Prevalence of uro-pathogens Culture report
from SVD
Susceptibility patterns for each bacterial strain Culture report
from SSI
Susceptibility patterns for each bacterial strain Culture report
from SVD
Prevalence of ESBL-resistant E. coli Culture report
from SSI
Prevalence of multi-resistant bacterial strains Culture report
from SVD
Risk factors for harboring ESBL-resistant E. coli Culture report
from SSI
n.a. n.a.
Patient questionnaire
SSI Statens Serum Institute, SVD SUND VET DIAGNOSTIK, ESBL extended spectrum beta-lactamase, n.a. not available
aReference laboratories
Table 3 Outcomes to assess the feasibility and synergistic value
of the One Health approach in human and veterinary primary
care practices in Denmark
Outcome
Feasibility • Number of clinicians recruited
• Number of patients recruited
• Recruitment speed rate of patients
• Number of patients followed-up
• Proportion of data completion
Synergistic value • Proportion of appropriate decisions to treat
with antibiotics for each diagnostic path
• Proportion of appropriate choices of
antibiotic for each diagnostic path
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will be obtained from all human participants and dog
owners.
Results of the study will be published in medical and
veterinary journals as well as in journals promoting the
One Health approach. The results of the project will be
presented in scientific conferences in which novel strat-
egies to curb the development of resistant bacterial
strains are discussed.
Discussion
This study is designed to contribute with unique in-
formation concerning the feasibility and synergistic
value of setting-up One Health projects in a clinical
context by comparing implementation outcomes as
well as the impact of the diagnostic process on
proper use of antibiotics in human and canine pa-
tients with suspected UTI.
Methodology—strengths and limitations
The most important strength of the study is the pragmatic
design. Hence, it is expected to increase applicability and
generalizability of the findings as it is a snap-shot of the
decision-making process during daily practice.
The pragmatic design is expected to encourage the
consecutive inclusion of the clinically relevant popula-
tion (i.e., all symptomatic patients with suspected UTI)
in order to avoid selection bias. Subgroup analyses of
the performance of the diagnostic pathways are per-
formed in order to avoid misinterpretation of the per-
formance of these pathways due to the case-mix of
patients (spectrum bias) [33].
Furthermore, we will control review bias [34] by
blinding the attending clinicians to the result of the
“gold standard”, while technicians assessing the gold
standard are blind to the results of the diagnostic
process and management. Finally, the diagnostic
Fig. 3 Definition of appropriate and inappropriate use of antibiotics. Appropriate use of antibiotics means that the decision about not giving antibiotics is
correct as far as the culture is negative or the bacteria is susceptible to the prescribed antibiotic. Inappropriate use of antibiotics can lead to two scenarios:
(a) under-treatment: a patient with a positive culture is not given antibiotics or the bacteria are not susceptible to the prescribed antibiotic and (b)
over-treatment: a patient with a negative culture is given antibiotics or is unnecessarily treated with a second-line antibiotic
Table 4 National Danish UTI treatment recommendations
General practice [38] Veterinary practice [39]
Acute uncomplicated cystitis
First-line antibiotics * Sulfamethizol 1 g × 2 for 3 days * Amoxicillin 10–15 mg/kg, PO, BID–TID ≤7 days
* Pivmecillinam 400 mg × 3 for 3 days * Sulfa/TMP 15 mg/kg, PO, BID ≤7 days
Second-line antibiotics * Trimethoprim 200 mg × 2 for 3 days * Amoxicillin/clavulanic acid 12.5–25 mg/kg, PO, BID–TID ≤7 days
* Nitrofurantoin 50 mg × 4 for 3 days * Enrofloxacin 5 mg/kg IM/SC/PO, SID ≤7 days
Acute complicated cystitis
First-line antibiotics * Sulfamethizol 1 g × 2 for 3 days * Amoxicillin 10–15 mg/kg, PO, BID–TID 7 days to 4 weeks
* Pivmecillinam 400 mg × 3 for 3 days * Sulfa/TMP 15 mg/kg, PO, BID 7 days to 4 weeks
Second-line antibiotics * Trimethoprim 200 mg × 2 for 3 days * Amoxicillin/clavulanic acid 12.5–20 mg/kg, PO, BID–TID 7 days to 4 weeks
* Nitrofurantoin 50 mg × 4 for 3 days * Enrofloxacin 5 mg/kg IM/SC/PO, SID 7 days to 4 weeks
Acute pyelonephritis
First-line antibiotics * Pivmecillinam 400 mg × 3 for 3 days * Amoxicillin/clavulanic acid 12.5–25 mg/kg IM/SC/PO, BID–TID 4–6 weeks
Second-line antibiotics * Ciprofloxacin 500 mg × 2 for 10 days * Enrofloxacin 5–20 mg/kg IM/SC/PO, SID 4–6 weeks
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pathways are not used to determine the final outcome
(incorporation bias).
The observational design of the study is however also an
important limitation. As we do not influence the diagnos-
tic and treatment procedures already used in the different
practices, the validity of the diagnostic pathways is af-
fected by the variation caused by inter-observer interpret-
ation, use of different commercial brands for the different
diagnostic tools, the preferences for using certain diagnos-
tic tools, and the tendency to prescribe antibiotics. We
expect to be able to quantify the impact of such variation
by developing hierarchical models with random effects
and performing sensitivity analysis for specific groups.
Although the study aims at recruiting a wide variety of
practices and veterinary clinics, we cannot rule out that
they will differ in some basic characteristics from the gen-
eral practice and veterinary clinic population. Hence,
when interpreting the results, we will need to assess the
extent of representativeness of our sample and stress out
that our results could be the most conservative scenario
as previous studies have shown that health professionals
participating in research studies or audits have a lower
prescription pattern in comparison with their counter-
parts that do not participate in this type of activities [35].
Finally, in human patients, we cannot control the way
patients collect the urine sample; nonetheless, there is
some evidence suggesting that the collection technique is
not important with regard to sample contamination [36].
One Health approach—challenges and opportunities
The lack of validated diagnostic strategies is a challenge
to both general practitioners and companion animal vet-
erinarians, when managing patients with suspected UTI.
The increasing number of antibiotics used for both ani-
mals and humans makes the One Health approach a
logic alternative strategy that can bring about effective
solutions. Nonetheless, it is crucial to know first to what
extent GPs and CAVs can work together and the rele-
vance of such work.
As stated by Lerner et al. [37], the philosophy of the
One Health approach needs to be written. In that sense,
we expect to contribute with state-of-the-art knowledge
about the feasibility and synergistic value, bearing in
mind that better cooperation and coordination does not
mean integration.
However, the potential identification of similar chal-
lenges in the diagnostic process, opens a unique possibility
to implement common interventions related to changing
clinical practice behavior (i.e., use of new technologies to
support the decision-making process, training to cope
with uncertainty) and hopefully promote rational anti-
biotic use in humans and dogs for the benefits of all parts.
Finally, it is important to highlight that there are several
difficulties on the road to One Health clinical projects. Lack
of a broad availability of funds that support this type of ini-
tiative has been the most important challenge in order to
design the study as aligned as possible. For example, the
second urine sample could not be funded on the veterinary
side, thus we will not obtain information about the micro-
biological recovery of the dogs after 2 weeks.
Conclusion
This is the first clinical research protocol aimed at ex-
ploring the feasibility and synergistic value of using the
One Health approach in a clinical context. Results from
this study are crucial, if we are to embrace the One
Health approach as a legitimate strategy. A strategy, in
which the advantages of the inter-disciplinary work can
bring about solutions to the diagnostic challenges en-
countered in daily practice, when making the decision
of prescribing antibiotics or not. Improving the accur-
acy of the diagnostic process could potentially reduce
the unnecessary prescription of antibiotics, which in
the long-term perspective could contribute with curb-
ing the development of resistant strains.
Current status
The recruitment phase has started. Thirty practices have
recruited 400 patients, while 96 veterinary clinics have
recruited 153 dogs.
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